Pfizer (NYSE:PFE) Shares Up 1.8% - Time to Buy?

Pfizer Inc. (NYSE:PFE - Get Free Report) rose 1.8% during trading on Tuesday . The stock traded as high as $22.46 and last traded at $22.44. Approximately 7,278,720 shares were traded during trading, a decline of 82% from the average daily volume of 40,325,357 shares. The stock had previously closed at $22.04.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. UBS Group decreased their target price on shares of Pfizer from $28.00 to $24.00 and set a "neutral" rating for the company in a research note on Tuesday, April 8th. Finally, Cantor Fitzgerald began coverage on shares of Pfizer in a research report on Tuesday. They set a "neutral" rating and a $24.00 price target on the stock. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, five have issued a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, Pfizer presently has a consensus rating of "Moderate Buy" and a consensus target price of $29.57.

Pfizer Trading Up 1.2 %

The company has a 50 day moving average of $24.81 and a 200 day moving average of $26.11. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock has a market capitalization of $126.48 billion, a price-to-earnings ratio of 15.83, a P/E/G ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer's quarterly revenue was up 24.7% on a year-over-year basis. During the same period in the previous year, the business posted $0.10 earnings per share. On average, research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Insider Activity at Pfizer

In other news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.06% of the company's stock.

Institutional Trading of Pfizer

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Retirement Wealth Solutions LLC purchased a new position in Pfizer during the 4th quarter worth $26,000. Rialto Wealth Management LLC acquired a new stake in shares of Pfizer during the 4th quarter valued at approximately $26,000. Clarity Asset Management Inc. acquired a new stake in shares of Pfizer in the 4th quarter worth approximately $27,000. Gould Capital LLC raised its holdings in Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares during the last quarter. Finally, Kohmann Bosshard Financial Services LLC acquired a new stake in Pfizer in the fourth quarter valued at $28,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.